You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Express Scripts
Boehringer Ingelheim
Moodys
Mallinckrodt

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Lumicitabine


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Lumicitabine?

Lumicitabine is an investigational drug.

There have been 6 clinical trials for Lumicitabine. The most recent clinical trial was a Phase 1 trial, which was initiated on November 16th 2017.

The most common disease conditions in clinical trials are Infection, Communicable Diseases, and Renal Insufficiency. The leading clinical trial sponsors are Janssen Research & Development, LLC, Janssen Pharmaceutica N.V., Belgium, and [disabled in preview].

There are six US patents protecting this investigational drug and one hundred and eighteen international patents.

Recent Clinical Trials for Lumicitabine
TitleSponsorPhase
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human MetapneumovirusJanssen Research & Development, LLCPhase 2
A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult ParticipantsJanssen Research & Development, LLCPhase 1
A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult ParticipantsJanssen Research & Development, LLCPhase 1

See all Lumicitabine clinical trials

Clinical Trial Summary for Lumicitabine

Top disease conditions for Lumicitabine
Top clinical trial sponsors for Lumicitabine

See all Lumicitabine clinical trials

US Patents for Lumicitabine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lumicitabine   Start Trial Antiviral compounds Alios BioPharma, Inc. (South San Francisco, CA)   Start Trial
Lumicitabine   Start Trial Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (San Francisco, CA)   Start Trial
Lumicitabine   Start Trial Substituted nucleosides, nucleotides and analogs thereof Alios BioPharma, Inc. (South San Francisco, CA)   Start Trial
Lumicitabine   Start Trial Substituted nucleosides, nucleotides and analogs thereof Alios BioPharma, Inc. (South San Francisco, CA)   Start Trial
Lumicitabine   Start Trial Substituted nucleosides, nucleotides and analogs thereof Alios BioPharma, Inc. (South San Francisco, CA)   Start Trial
Lumicitabine   Start Trial Methods of preparing substituted nucleoside analogs Alios BioPharma, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lumicitabine

Drugname Country Document Number Estimated Expiration Related US Patent
Lumicitabine Australia 2016222729 2035-02-25   Start Trial
Lumicitabine Brazil 112017018022 2035-02-25   Start Trial
Lumicitabine Canada 2977150 2035-02-25   Start Trial
Lumicitabine China 107922427 2035-02-25   Start Trial
Lumicitabine Eurasian Patent Organization 201791886 2035-02-25   Start Trial
Lumicitabine European Patent Office 3262048 2035-02-25   Start Trial
Lumicitabine Israel 254011 2035-02-25   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Colorcon
Express Scripts
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.